SCHEMBL22249155

SCHEMBL22249155

COc1cc(OCCCF)ccc1COc1cnn(C(C)(C)C)c(=O)c1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 6/20 0.44
LMNA P02545 2/20 0.44
NPSR1 Q6W5P4 1/20 0.40
HTT P42858 2/20 0.38
HPGD P15428 1/20 0.38
ATM Q13315 1/20 0.38
ALDH1A1 P00352 4/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
RAB9A P51151 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
GALR3 O60755 1/20 0.35
NR2F2 P24468 1/20 0.35
GPR183 P32249 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30569526 0.90 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL15566998 0.90 SMN1; SMN2 (0.45) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL30569532 0.89 SMN1; SMN2 (0.47) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL15567216 0.89 SMN1; SMN2 (0.47) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL12722501 0.84 SMN1; SMN2 (0.46) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL1627237 0.84 SMN1; SMN2 (0.46) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL15566528 0.84 SMN1; SMN2 (0.41) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL21442599 0.83 SMN1; SMN2 (0.55) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL15566293 0.82 SMN1; SMN2 (0.53) SMN1; SMN2LMNANPSR1HTTHPGD
SCHEMBL16901938 0.82 SMN1; SMN2 (0.47) SMN1; SMN2LMNANPSR1HTTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents LANTHEUS MEDICAL IMAGING, INC. (US) 2023-09-05 US disclosed
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS LANTHEUS MEDICAL IMAGING, INC. (US) 2020-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200230264-A1 COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885NPSR1 146/4885
US-11744906-B2 Compositions, methods, and systems for the synthesis and use of imaging agents FABP3, TNNI3, TNNT2 SMN1; SMN2 699/4885LMNA 1449/4885NPSR1 146/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.